Sitravatinib plus nivolumab fails to extend survival in phase 3 lung cancer study
Click Here to Manage Email Alerts
The addition of sitravatinib to nivolumab failed to extend OS, when compared with docetaxel, among certain patients with nonsquamous non-small cell lung cancer, according to topline data from the agent’s manufacturer.
Sitravatinib (Mirati Therapeutics) is an investigational spectrum-selective kinase inhibitor.
The phase 3 SAPPHIRE study evaluated the addition of sitravatinib to the PD-1 inhibitor nivolumab (Opdivo, Bristol Myers Squibb) among patients with second- or third-line advanced nonsquamous NSCLC who had progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy.
The study did not meet the primary endpoint of OS upon final analysis, the company announced in a press release.
“Mirati extends gratitude to the patients who participated in this clinical trial, their loved ones, and the trial investigators, without whom important work like this would not have been possible,” Alan Sandler, MD, chief medical officer of Mirati Therapeutics, said in the press release. “As we move forward, we are optimistic about our ability to positively impact the lives of patients living with cancer through the advancement of our broad and differentiated pipeline of targeted oncology programs.”
Mirati plans to present SAPPHIRE data at a future medical meeting.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts